Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2024-10-08 Director's Dealing
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-10-08 English
Director's Dealing 2024
Director's Dealing
2024-10-08 English
Director's Dealing 2024
Director's Dealing
2024-10-08 English
Director's Dealing 2024
Director's Dealing
2024-10-08 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes the completion of a merger transaction, including details about the merger agreement, reverse stock split, name change, stock reclassification, PIPE investment, and other corporate actions. It also references a prior proxy statement/prospectus filed on Form S-4. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The primary content is the announcement of the completion of a merger and related corporate actions, which fits the category of M&A Activity (TAR). The length and detail confirm it is not a brief announcement or a report publication announcement. Therefore, the appropriate classification is M&A Activity (TAR).
2024-10-08 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 2, 2024, reporting the submission of matters to a vote of security holders at a special meeting held on September 26, 2024. It details the voting results on several proposals related to a merger agreement and other corporate actions. The document includes detailed vote counts for each proposal and references the definitive proxy statement filed earlier. The content is focused on the official results of shareholder votes at a meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual or quarterly report, nor is it a proxy solicitation or a merger filing itself, but specifically the voting results from the meeting. Therefore, the appropriate classification is DVA with high confidence.
2024-10-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.